Brookstone Capital Management Biogen Inc. Transaction History

Brookstone Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 11, 2023	BUY	$275.25 - $318.06 $938,877 - $1.08 Million	3,411 Added 29.45%	14,994 $4.27 Million
Q1 2023 Apr 18, 2023	BUY	$256.56 - $292.34 $755,312 - $860,648	2,944 Added 34.08%	11,583 $3.22 Million
Q4 2022 Jan 09, 2023	BUY	$252.44 - $306.72 $354,425 - $430,634	1,404 Added 19.41%	8,639 $0
Q3 2022 Oct 13, 2022	BUY	$194.69 - $268.46 $436,494 - $601,887	2,242 Added 44.9%	7,235 $1.84 Million
Q2 2022 Jul 11, 2022	BUY	$187.54 - $223.02 $173,662 - $206,516	926 Added 22.77%	4,993 $1.09 Million
Q1 2022 Apr 12, 2022	BUY	$193.77 - $244.14 $369,906 - $466,063	1,909 Added 88.46%	4,067 $857,000
Q4 2021 Jan 11, 2022	BUY	$223.92 - $287.77 $91,583 - $117,697	409 Added 23.38%	2,158 $502,000
Q3 2021 Nov 03, 2021	BUY	$282.99 - $369.05 $303,648 - $395,990	1,073 Added 158.73%	1,749 $496,000
Q2 2021 Jul 14, 2021	BUY	$259.0 - $414.71 $175,084 - $280,343	676 New	676 $238,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

Stay updated on Brookstone Capital Management with notifications on news.